Document Detail


Serotonergic and Adrenergic Drug Interactions Associated with Linezolid: A Critical Review and Practical Management Approach (April).
MedLine Citation:
PMID:  23548646     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
OBJECTIVE:To describe the evidence for serotonergic and adrenergic drug interactions with linezolid and discuss clinical management strategies.DATA SOURCES:A literature search of PubMed (1947-November 2012), MEDLINE (1946-November 2012), EMBASE (1974-November 2012), and International Pharmaceutical Abstracts (1970-November 2012) was conducted using the terms linezolid, drug interaction, serotonin syndrome, serotonin toxicity, sympathomimetic, serotonergic agents, and adrenergic agents. Citations of retrieved articles were also reviewed.STUDY SELECTION AND DATA EXTRACTION:English-language articles describing coadministration of serotonergic or adrenergic agents with linezolid to humans were included. Studies published only in abstract form were excluded.DATA SYNTHESIS:One prospective study, 6 retrospective studies, and 24 case reports were identified describing a serotonergic or adrenergic drug interaction. Incidence of serotonin syndrome in patients on linezolid and serotonergic agents ranged between 0.24% and 4%. Serotonergic agents determined to have probable (according to the Horn Drug Interaction Probability Scale) linezolid interactions in case reports included meperidine, citalopram, escitalopram, fluoxetine, paroxetine, sertraline, duloxetine, and venlafaxine. Serotonergic agent dose and duration of coadministration with linezolid did not appear to influence the occurrence of serotonin syndrome. Adrenergic medication coadministration was associated with a possible drug interaction as determined by the Horn Drug Interaction Probability Scale but did not appear to result in clinically significant drug interactions with linezolid.CONCLUSIONS:Linezolid-associated serotonergic drug interactions occur more commonly than adrenergic interactions. Serotonergic interactions considered probable according to the Horn Drug Interaction Probability Scale do not appear to correlate with drug dosage; time of onset ranges from <1 to 20 days, and effect resolves in <1 to 5 days after discontinuation of offending agents. If coadministration of linezolid and a serotonergic agent cannot be avoided, clinicians should be aware of the symptoms and management of serotonergic toxicity; close monitoring is recommended and additional serotonergic agents should not be used. While adrenergic drug interactions with linezolid are less common in clinical practice, monitoring for signs of hypertension remains important.
Authors:
Tasha D Ramsey; Tim Ty Lau; Mary Hh Ensom
Related Documents :
24166236 - Development times, clinical testing, postmarket follow-up, and safety risks for the new...
20562456 - Effect of hyperventilation on seizure activation: potentiation by antiepileptic drug ta...
23107106 - Drug and therapeutics committees in danish hospitals: a survey of organization, activit...
24840156 - The new pattern of drug abuse in china.
11334936 - Transporters in african trypanosomes: role in drug action and resistance.
11470606 - Microtubule-stabilizing agents: a growing class of important anticancer drugs.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-4-2
Journal Detail:
Title:  The Annals of pharmacotherapy     Volume:  -     ISSN:  1542-6270     ISO Abbreviation:  Ann Pharmacother     Publication Date:  2013 Apr 
Date Detail:
Created Date:  2013-4-3     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9203131     Medline TA:  Ann Pharmacother     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
< The University of British Columbia, Vancouver, British Columbia, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Safety of New Oral Anticoagulants with Dual Antiplatelet Therapy in Patients with Acute Coronary Syn...
Next Document:  Current Approaches to Punitive Action for Medication Errors by Boards of Pharmacy (April).